CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (Unaudited) - USD ($) $ in Thousands	Common Stock	Additional Paid-In Capital	Retained Earnings	Accumulated Other Comprehensive Earnings	Noncontrolling Interest	Total
Beginning balance at Dec. 31, 2022	$ 61,618	$ 294,029	$ 2,217,410	$ (9,075)	$ 32,841	$ 2,596,823
Increase (Decrease) in Stockholders' Equity
Net earnings (loss)			126,069		(313)	125,756
Foreign currency translation adjustment				3,850	2,195	6,045
Unrealized gain (loss) on debt securities				151		151
Distributions to NCI					(4,859)	(4,859)
Cash dividends			(15,642)			(15,642)
Issuance of shares under employee stock purchase plan	10	675				685
Issuance of shares under stock grant programs	825	14,356	6			15,187
Issuance of shares under deferred compensation plans	93	(93)
Repurchase of shares	(450)		(34,818)			(35,268)
Expense associated with share-based compensation arrangements		9,598				9,598
Accrued expense under deferred compensation plans		7,165				7,165
Ending balance at Apr. 01, 2023	62,096	325,730	2,293,025	(5,074)	29,864	2,705,641
Beginning balance at Dec. 30, 2023	61,621	354,702	2,582,332	1,106	30,429	3,030,190
Increase (Decrease) in Stockholders' Equity
Net earnings (loss)			120,791		622	121,413
Foreign currency translation adjustment				(1,419)	616	(803)
Unrealized gain (loss) on debt securities				6		6
Distributions to NCI					(3,331)	(3,331)
Cash dividends			(20,411)			(20,411)
Issuance of shares under employee stock purchase plan	6	648				654
Issuance of shares under stock grant programs	369	5,829				6,198
Issuance of shares under deferred compensation plans	77	(77)
Repurchase of shares	(319)	(17,686)	(18,631)			(36,636)
Expense associated with share-based compensation arrangements		11,194				11,194
Accrued expense under deferred compensation plans		7,621				7,621
Ending balance at Mar. 30, 2024	$ 61,754	$ 362,231	$ 2,664,081	$ (307)	$ 28,336	$ 3,116,095